Submissions from 2021
Lumican, Pro-tumorigenic or Anti-tumorigenic: A Conundrum, Muni Rubens, Anshul Saxena, Peter McGranaghan, Yazmin Odia, and Rupesh Kotecha
Full Text Restricted – Available from BHSF IP or login only
Hospitalization rates for complications due to systemic therapy in the United States, Anshul Saxena, Muni Rubens, Venkataraghavan Ramamoorthy, Raees Tonse, Emir Veledar, Peter McGranaghan, Michael Chuong, Matthew Hall, Yazmin Odia, Minesh Mehta, and Rupesh Kotecha
Chemotherapy-induced changes in tumor consistency can allow gross total resection of previously unresectable brainstem pilocytic astrocytoma, Vitaly Siomin and Yazmin Odia
Open Access
Submissions from 2020
HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA, Minesh Mehta, Yazmin Odia, Matthew Hall, and Doured Daghistani
Open Access
Biological activity of weekly ONC201 in adult recurrent glioblastoma patients, Yazmin Odia and Minesh Mehta
Full Text Restricted – Available from BHSF IP or login only
Early imaging marker of progressing glioblastoma: a window of opportunity, Yazmin Odia and Minesh Mehta
Full Text Restricted – Available from BHSF IP or login only
Recent Health Care Expenditure Trends Among Adult Cancer Survivors in United States, 2009-2016, Muni Rubens, Anshul Saxena, Sankalp Das, Chintan Bhatt, Emir Veledar, Peter McGranaghan, Ana Viamonte Ros, Yuliya Linhares, Yazmin Odia, Michael Chuong, Rupesh Kotecha, and Minesh Mehta
Full Text Restricted – Available from BHSF IP or login only
Submissions from 2019
EBV-positive primary CNS lymphoma restricted to the conus medullaris in an immunocompetent host, Matthew Hall, Lyle Feinstein, Sergio Gonzalez-Arias, and Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only
First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report, Matthew Hall, Yazmin Odia, Doured Daghistani, and Minesh Mehta
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201, Matthew Hall, Yazmin Odia, and Minesh Mehta
Full Text Restricted – Available from BHSF IP or login only
Core curriculum guidelines for a required clinical neurology experience, Yazmin Odia
Open Access
Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations, Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only
Submissions from 2017
Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options, Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only
BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors, Ashley Roque and Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only
Submissions from 2016
Gangliocytomas and Gangliogliomas: Review of Clinical, Pathologic and Genetic Features, Yazmin Odia
Open Access
Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy, Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only